[1] Kovesdy C P.Epidemiology of chronic kidney disease: an update 2022[J]. Kidney Int Suppl, 2022,12(1):7-11.
[2] 上海市肾内科临床质量控制中心专家组. 慢性肾脏病早期筛查、诊断及防治指南(2022年版)[J]. 中华肾脏病杂志,2022,38(5):453-464.
[3] Nimitphong H, Saetung S, Chailurkit L O, et al. Vitamin D supplementation is associated with serum uric acid concentration in patients with prediabetes and hyperuricemia[J]. J Clin Transl Endocrinol, 2021,24:100255.
[4] Collaborators GELE.Changing life expectancy in European countries 1990-2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021[J]. Lancet Public Health, 2025,10(3):e172-e188.
[5] Vassalotti J A, Francis A, Soares DSACJ, et al. Are your kidneys Ok? Detect early to protect kidney health[J]. Kidney Int, 2025,107(3):370-377.
[6] Ketteler M, Evenepoel P, Holden R M, et al. Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2025,107(3):405-423.
[7] Stack A G.Can we crystallize the role of urate-lowering treatment in chronic kidney disease?[J]. Kidney Int, 2025,107(3):394-396.
[8] Wen Y, Xu L, Melchinger I, et al. Longitudinal biomarkers and kidney disease progression after acute kidney injury[J]. JCI Insight, 2023,8(9):e167731.
[9] Ebert T, Pawelzik S C, Witasp A, et al. Inflammation and premature ageing in chronic kidney disease[J]. Toxins (Basel), 2020,12(4):227.
[10] Huang W, Luo L.Interactive effects of vitamin D and serum uric acid concentration on protein-energy wasting in maintenance hemodialysis patients[J]. Cell Mol Biol (Noisy-le-grand), 2023,69(15):108-113.
[11] Isnuwardana R, Bijukchhe S, Thadanipon K, et al. Association between vitamin D and uric acid in adults: a systematic review and meta-analysis[J]. Horm Metab Res, 2020,52(10):732-741.
[12] Charoenngam N, Ponvilawan B, Ungprasert P.Vitamin D insufficiency and deficiency are associated with a higher level of serum uric acid: a systematic review and meta-analysis[J]. Mod Rheumatol, 2020,30(2):385-390.
[13] Riccio P.Vitamin D, the sunshine molecule that makes us strong: what does its current global deficiency imply?[J]. Nutrients, 2024,16(13):2015.
[14] Cui A, Zhang T, Xiao P, et al. Global and regional prevalence of vitamin D deficiency in population-based studies from 2000 to 2022: a pooled analysis of 7.9 million participants[J]. Front Nutr, 2023,10:1070808.
[15] Solarin A U, Nourse P, Gajjar P.Vitamin D status of children with moderate to severe chronic kidney disease at a tertiary pediatric center in cape town[J]. Saudi J Kidney Dis Transpl, 2019,30(4):781-794.
[16] Ganimusa I, Chew E, Lu E M.Vitamin D deficiency, chronic kidney disease and periodontitis[J]. Medicina (Kaunas), 2024,60(3):420.
[17] Song S, Lyu J, Song B M, et al. Serum 25-hydroxyvitamin D levels and risk of all-cause and cause-specific mortality: a 14-year prospective cohort study[J]. Clin Nutr, 2024,43(9):2156-2163.
[18] Minisola S, Merlotti D.The effect of vitamin D on metabolic bone disease and chronic diseases[J]. Nutrients, 2023,15(22):4775.
[19] 王志强,李贤慧. 维生素D缺乏与多系统疾病相关性的研究进展[J]. 武警医学,2021,32(4):358-361.
[20] 秦力维,刘洋,王凤翔.维生素D与眼科疾病相关性研究进展[J]. 武警医学,2025,36(1):82-86.
[21] 任佳丽, 马金娜, 熊杰. 维生素D代谢与军人应力性骨折的关联性[J]. 武警医学,2022,33(4):353-357.
[22] Lee J, Bae E H, Kim S W, et al.The association between vitamin D deficiency and risk of renal event: results from the Korean cohort study for outcomes in patients with chronic kidney disease (KNOW-CKD)[J]. Front Nutr, 2023,10:1017459.
[23] Franca GPH, Wolley M, Ranganathan D, et al. Vitamin D deficiency in chronic kidney disease: recent evidence and controversies[J]. Int J Environ Res Public Health, 2018,15(8):1773.
[24] Brandenburg V, Ketteler M.Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future[J]. Nutrients, 2022,14(15):3009.
[25] Vervloet M G, Hsu S, de Boer I H. Vitamin D supplementation in people with chronic kidney disease[J]. Kidney Int, 2023,104(4):698-706.
[26] Yeung W G, Toussaint N D, Badve S V. Vitamin D therapy in chronic kidney disease: a critical appraisal of clinical trial evidence[J]. Clin Kidney J, 2024,17(8):sfae227.
[27] Junarta J, Jha V, Banerjee D.Insight into the impact of vitamin D on cardiovascular outcomes in chronic kidney disease[J]. Nephrology (Carlton), 2019,24(8):781-790.
[28] Kara A V, Aldemir M N, Soylu Y E, et al. Relationship between serum Vitamin D levels and health-related quality of life in maintenance hemodialysis patients[J]. Blood Purif, 2019,48(1):67-75.
[29] Jorgensen H S, Vervloet M, Cavalier E, et al. The role of nutritional vitamin D in CKD-MBD in children and adults with CKD, on dialysis and after kidney transplantation - a European consensus statement[J]. Nephrol Dial Transplant, 2025,40(4):797-822.
[30] Du L, Zong Y, Li H, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy[J]. Signal Transduct Target Ther, 2024,9(1):212.
[31] Cicero A, Fogacci F, Di Micoli V, et al. Purine metabolism dysfunctions: experimental methods of detection and diagnostic potential[J]. Int J Mol Sci, 2023,24(8):7027.
[32] Wen S, Arakawa H, Tamai I.Uric acid in health and disease: from physiological functions to pathogenic mechanisms[J]. Pharmacol Ther, 2024,256:108615.
[33] Gherghina M E, Peride I, Tiglis M, et al. Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment[J]. Int J Mol Sci, 2022,23(6):3188.
[34] Dominguez-Zambrano E, Pedraza-Chaverri J, Lopez-Santos AL, et al. Association between serum uric acid levels, nutritional and antioxidant status in patients on hemodialysis[J]. Nutrients, 2020,12(9):2600.
[35] Sato Y, Feig D I, Stack A G, et al. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD[J]. Nat Rev Nephrol, 2019,15(12):767-775.
[36] Su H Y, Yang C, Liang D, et al. Research advances in the mechanisms of hyperuricemia-induced renal injury[J]. Biomed Res Int, 2020:5817348.
[37] Oh T R, Choi H S, Kim C S, et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study[J]. Sci Rep, 2019,9(1):6681.
[38] 中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南(2019)[J]. 中华内分泌代谢杂志,2020,36(1):1-13.
[39] Nishino M, Egami Y, Kawanami S, et al. Lowering uric acid may improve prognosis in patients with hyperuricemia and heart failure with preserved ejection fraction[J]. J Am Heart Assoc, 2022,11(19):e026301.
[40] Wu S, Xue W, Yu H, et al. Serum uric acid levels and health outcomes in CKD: a prospective cohort study[J]. Nephrol Dial Transplant, 2024,39(3):510-519.
[41] Kanbay M, Afsar B, Siriopol D, et al. Effect of uric acid-lowering agents on cardiovascular outcome in patients with heart failure: a systematic review and meta-analysis of clinical studies[J]. Angiology, 2020,71(4):315-323.
[42] Zhang S, Xie Q, Xie S, et al. The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): a network meta-analysis of randomized trials[J]. Pharmacotherapy, 2021,41(9):781-791.
[43] 陈江华, 何强,徐莹,等. 维持性血液透析患者微炎症状态的认识与防治[J]. 中华肾脏病杂志,2005,21(2):117-118.
[44] Wu J, Guo N, Chen X, et al. Coexistence of micro-inflammatory and macrophage phenotype abnormalities in chronic kidney disease[J]. Int J Clin Exp Pathol, 2020,13(2):317-323.
[45] Liu X Q, Jiang T T, Wang M Y, et al. Using machine learning to evaluate the role of microinflammation in cardiovascular events in patients with chronic kidney disease[J]. Front Immunol, 2021,12:796383.
[46] Gao W, Wang X, Zou Y, et al. Progress in the application of novel inflammatory indicators in chronic kidney disease[J]. Front Med (Lausanne), 2025,12:1500166.
[47] Yin W, Zhou Q L, OuYang S X, et al. Uric acid regulates NLRP3/IL-1beta signaling pathway and further induces vascular endothelial cells injury in early CKD through ROS activation and K(+) efflux[J]. BMC Nephrol, 2019,20(1):319.
[48] Zhang X, Wang Y, Yin Y, et al. Changes of gut microbiota in maintenance hemodialysis patients and their impact on patient's microinflammation status[J]. Cell Mol Biol (Noisy-le-grand), 2023,69(8):96-101.
[49] Goicoechea M, de Vinuesa S G, Quiroga B,et al. Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study)[J]. Cardiovasc Drugs Ther, 2018,32(3):255-263.
[50] Lu J L, Shrestha P, Streja E, et al. Association of long-term aspirin use with kidney disease progression[J]. Front Med (Lausanne), 2023,10:1283385.
[51] Tu Y, Fang Q J, Sun W, et al. Total flavones of abelmoschus manihot remodels gut microbiota and inhibits microinflammation in chronic renal failure progression by targeting autophagy-mediated macrophage polarization[J]. Front Pharmacol, 2020,11:566611.
[52] Chen Z, Lin Y, Wang J, et al. Relationship between compound alpha-ketoacid and microinflammation in patients with chronic kidney disease[J]. Curr Pharm Des, 2024,30(8):589-596.
[53] Dai H X, Zhao Z Y, Xia Y, et al. Higher levels of high-sensitivity C-reactive protein is positively associated with the incidence of hyperuricemia in chinese population: a report from the china health and retirement longitudinal study[J]. Mediators Inflamm, 2020,2020:3854982.
[54] Van Etten E, Mathieu C.Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts[J]. J Steroid Biochem Mol Biol, 2005,97(1-2):93-101.
[55] Zhou A, Hypponen E.Vitamin D deficiency and C-reactive protein: a bidirectional mendelian randomization study[J]. Int J Epidemiol, 2023,52(1):260-271.
[56] 中国医师协会肾脏内科医师分会维生素D实践方案专家协作组. 维生素D及其类似物在慢性肾脏病患者中应用的中国实践方案(2019版)[J]. 中华内科杂志,2020,59(2):104-116.
[57] Group KDIGO.KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int, 2024,105(4S):S117-S314.
[58] 中国民族卫生协会重症代谢疾病分会, 高尿酸血症相关疾病诊疗多学科共识专家组,中国高尿酸血症相关疾病诊疗多学科专家共识(2023年版)[J]. 中国实用内科杂志,2023,43(6):461-480.
[59] 中国慢性肾脏病患者合并高尿酸血症诊治共识专家组.中国慢性肾脏病患者合并高尿酸血症诊治专家共识[J].中华肾脏病杂志,2017,33(6):463-469.